Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2013. The report details a specific share repurchase transaction executed on March 7, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 370,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,487.5 pence per share; lowest price paid was 1,477.5 pence per share.
- Treasury Holdings (Settled): 494,951,327 shares (9.16% of total issued share capital).
- Treasury Holdings (Including Unsettled): 495,321,327 shares (10.09% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,907,305,473 shares.
Material Changes
The filing reports an incremental increase in the Company's treasury share holdings following the purchase of 370,000 shares. This transaction increased the percentage of total voting rights held in treasury to 10.09% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a routine disclosure of a share repurchase and does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (494,951,327 settled) against the Company's latest annual report.
- Confirm the total issued share capital to validate the 9.16% treasury ownership calculation.
- Check the status of the 370,000 shares purchased to ensure settlement is complete for the 10.09% voting rights figure.
- Review the remaining authority under the May 3, 2012 shareholder mandate for future buybacks.